Hepatocellular carcinoma (HCC) is the most common primary liver tumour (80-90%) and represents more than 5.7% of all cancers. Although in recent years the therapeutic options for these patients have increased, clinical results are yet unsatisfactory and the prognosis remains dismal. Clinical or molecular criteria allowing a more accurate selection of patients are in fact largely lacking.
Intervento di Frey
Caso clinico: Paziente di 25 anni con litiasi del dotto di Wirsung associato a pancreatite cronica complicata da dolori invalidanti postprandiali.
Intervento:svuotamento parenchimale cefalico con estrazione della litiasi e realizzazione di una anastomosi wirsungdigiunale su ansa ad «Y»
Decorso postoperatorio normale e rientro a domicilio in sesta giornata
Lettura consigliata: SURGICAL TREATMENT OF CHRONIC PANCREATITIS
Hepatocellular carcinoma (HCC) represent actually the fifth most common cancer worldwide, with liver transplantation and hepatic resection who represent the standard of care of curative treatment. Unfortunately, not all patient could benefit of curative treatment. For such patients, locoregional or systemic therapies represent a valid option in order to achieve the best survival possible.
Robotic pancreaticoduodenectomy and distal pancreatectomy: State of the art.
Memeo R, Sangiuolo F, de Blasi V, Tzedakis S, Mutter D, Marescaux J, Pessaux P.
J Visc Surg. 2016
Abstract:Over recent years, minimally invasive pancreatic resections have increasingly been reported in the literature.
Universitary Diploma of HPB and Transplantation 2-3-4 June 2016 Strasbourg
